Celltrion Healthcare gets EC approval for infliximab’s biosimilar Remsima SC

This article was originally published here

Remsima SC is claimed to be the world’s first subcutaneous formulation of infliximab. The EC approval was based on clinical evidence, including results from a study that demonstrated

The post Celltrion Healthcare gets EC approval for infliximab’s biosimilar Remsima SC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply